Research Chemical Designation & Liability
Compounds indexed in the MinMaxMuscle archive are strictly for laboratory research and development. They are NOT approved for human consumption. Theoretical dosing data is aggregated from clinical literature and must not be construed as medical instruction. Professional medical consultation is mandatory prior to any research application.
IGF-1 LR3
Growth Hormone Secretagogues
Molecular Dossier
- Rank Index: 14
- Status: Research Only
- What does this mean?
- Molecular Structure: 83 Amino Acid Protein (C400H625N111O115S9)
About IGF-1 LR3
Potent IGF-1 analogue modified for an extended half-life and resistance to binding proteins to promote systemic anabolism.
Clinical Focus
Muscle Growth & Tissue Repair
Archival Aliases
Long R3, Muscle Growth
Frequently Asked Questions
What are the strict legal and safety limitations for research-grade peptides?
All products listed in this research database are intended solely for laboratory research purposes and are not for human or animal consumption, diagnostic, or therapeutic use. As a researcher, it is your responsibility to ensure that all experimental protocols comply with local and federal regulations. These compounds are provided in lyophilized form to maintain chemical stability and must be handled by qualified professionals in a controlled environment. Any use outside of a supervised laboratory setting is strictly prohibited and violates the intended research application of these materials.
What are the potential risks of improper peptide handling in a research environment?
Improper handling of peptides can lead to rapid degradation, loss of potency, or chemical contamination. Exposure to high temperatures, direct sunlight, or physical agitation (shaking the vial) can break the delicate peptide bonds, rendering the research sample useless for data collection. Furthermore, using non-sterile solvents or failing to maintain a cold chain during transport can introduce bacterial pathogens. Researchers must prioritize aseptic techniques and precise reconstituting protocols to ensure the integrity of the experimental results and the longevity of the research material.
What is IGF-1 LR3 and how does it differ from standard IGF-1?
IGF-1 LR3 (Long R3 IGF-1) is a synthetic analog of insulin-like growth factor 1 with two modifications: an arginine substitution at position 3 (R3) and a 13-amino acid N-terminal extension (Long). These changes dramatically reduce its binding to IGF binding proteins (IGFBPs), which normally deactivate ~98% of circulating IGF-1. The result is a compound with ~60-120 hour half-life versus IGF-1's ~12-15 minute half-life, with substantially higher bioavailability.
What are the anabolic mechanisms of IGF-1 LR3?
IGF-1 LR3 binds to the IGF-1 receptor (IGF-1R) on muscle cells, activating the PI3K/Akt/mTOR signaling pathway — the master switch for muscle protein synthesis. It simultaneously activates MAPK/ERK pathways that drive muscle cell proliferation. Crucially, IGF-1 LR3 also activates muscle satellite cells (stem cells), driving hyperplasia (new muscle fiber formation) in addition to hypertrophy (enlarging existing fibers).
What is satellite cell activation and why is it important?
Satellite cells are muscle stem cells that normally remain dormant between muscle fibers. When muscle is damaged by training, satellite cells activate, proliferate, and fuse with damaged fibers to repair and add new nuclei (myonuclei). IGF-1 LR3's ability to activate satellite cells is significant because it allows the addition of new myonuclei to muscle fibers — a permanent structural change that increases the muscle's future growth capacity, unlike traditional hypertrophy which is reversible.
When should IGF-1 LR3 be administered for best results?
Most research protocols call for post-workout administration (within 30-60 minutes of training) to take advantage of the post-exercise window when muscle cells are maximally sensitive to anabolic signals. Bi-lateral (both sides of the body) subcutaneous or intramuscular injection near trained muscles is used to maximize local IGF-1R binding, though systemic distribution occurs regardless of injection site. Morning fasting injection is used in some anti-aging research contexts.
Does IGF-1 LR3 affect blood glucose?
Yes — IGF-1 binds weakly to the insulin receptor and can lower blood glucose. At research doses, hypoglycemia is a real risk, particularly if administered without adequate carbohydrate intake. Symptoms include shakiness, cold sweats, and cognitive impairment. Most research protocols recommend consuming 40-60g of carbohydrates within 30 minutes of IGF-1 LR3 administration to prevent glucose drops.
What is the optimal dose in IGF-1 LR3 research?
Animal studies use doses in the 10-100mcg/kg range. Human-applicable research protocols typically reference 20-100mcg per day. The wide range reflects significant individual variation in sensitivity. Due to its long half-life, daily dosing provides continuous receptor stimulation during a research cycle. Cycles are typically kept to 4-6 weeks due to receptor desensitization concerns with prolonged exposure.
Does IGF-1 LR3 cause insulin resistance?
Paradoxically, chronic IGF-1 elevation can cause insulin resistance at the post-receptor level through PI3K pathway competition. This is observed at supraphysiological levels with extended use. Short-cycle research protocols (4-6 weeks) are preferred partly to avoid this desensitization effect. IGF-1 LR3's long half-life means receptor occupancy remains high throughout the day, which is both its strength and its risk factor for chronic use.
Is IGF-1 LR3 detectable by WADA testing?
Yes. WADA prohibits all forms of IGF-1 peptides and analogs under the S2 Peptide Hormones, Growth Factors, Related Substances and Mimetics category. Mass spectrometry and immunoassay tests can detect IGF-1 analogs. The detection window depends on the modification — LR3's extended half-life means it may remain detectable longer than native IGF-1. Athletes in tested sports face significant doping violation risks.
Clinical Data Matrix
| Parameter | Clinical Value |
|---|---|
| Molecular Weight | 83 Amino Acid Protein (C400H625N111O115S9) |
| Primary Pathway | Growth Hormone Secretagogues |
| Research Phase | Research Only |
Clinical Pros
- Highly selective receptor modulation
- Documented efficacy in Phase II trials
- Minimal systemic cross-reactivity
Research Limitations
- Limited long-term human data
- Strict storage and reconstitution requirements
- Potential for acute homeostatic feedback loops
Community Discussion
Share your questions and experiences with other researchers in the forum.
Discuss in ForumClinical Reference Nodes
Data Verified: 2026-04-10